|
1
|
Gormley JA, Hegarty SM, O'Grady A,
Stevenson MR, Burden RE, Barrett HL, Scott CJ, Johnston JA, Wilson
RH, Kay EW, et al: The role of cathepsin S as a marker of prognosis
and predictor of chemotherapy benefit in adjuvant CRC: A pilot
study. Br J Cancer. 105:1487–1494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nikolouzakis TK, Vassilopoulou L,
Fragkiadaki P, Mariolis Sapsakos T, Papadakis GZ, Spandidos DA,
Tsatsakis AM and Tsiaoussis J: Improving diagnosis, prognosis and
prediction by using biomarkers in CRC patients (Review). Oncol Rep.
39:2455–2472. 2018.PubMed/NCBI
|
|
3
|
Wu J, Wang F, Liu X, Zhang T, Liu F, Ge X,
Mao Y and Hua D: Correlation of IDH1 and B7H3 expression with
prognosis of CRC patients. Eur J Surg Oncol. 44:1254–1260. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Costa DF and Torchilin VP: Micelle-like
nanoparticles as siRNA and miRNA carriers for cancer therapy.
Biomed Microdevices. 20:592018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu B, Liu J, Xiang X, Liu S, Zhong P, Xie
F, Mou T and Lai L: Expression of miRNA-143 in pancreatic cancer
and its clinical significance. Cancer Biother Radiopharm.
33:373–379. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen Y, Zhao J, Luo Y, Wang Y and Jiang Y:
Downregulated expression of miRNA-149 promotes apoptosis in side
population cells sorted from the TSU prostate cancer cell line.
Oncol Rep. 36:2587–2600. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ju H, Tan JY, Cao B, Song MQ and Tian ZB:
Effects of miR-223 on colorectal cancer cell proliferation and
apoptosis through regulating FoxO3a/BIM. Eur Rev Med Pharmacol Sci.
22:3771–3778. 2018.PubMed/NCBI
|
|
8
|
Su M, Qin B, Liu F, Chen Y and Zhang R:
miR-885-5p upregulation promotes colorectal cancer cell
proliferation and migration by targeting suppressor of cytokine
signaling. Oncol Lett. 16:65–72. 2018.PubMed/NCBI
|
|
9
|
Li L, Zhang X, Yi Z, Liang X, Yin W and Li
S: MiR-503 promotes the migration and invasion of colorectal cancer
cells by regulating PDCD4. J BUON. 23:579–586. 2018.PubMed/NCBI
|
|
10
|
Afshar S, Najafi R, Sedighi Pashaki A,
Sharifi M, Nikzad S, Gholami MH, Khoshghadam A, Amini R, Karimi J
and Saidijam M: MiR-185 enhances radiosensitivity of colorectal
cancer cells by targeting IGF1R and IGF2. Biomed Pharmacother.
106:763–769. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tian X, Wei Z, Wang J, Liu P, Qin Y and
Zhong M: MicroRNA-429 inhibits the migration and invasion of colon
cancer cells by targeting PAK6/cofilin signaling. Oncol Rep.
34:707–714. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Petit A, Ragu C, Della-Valle V,
Mozziconacci MJ, Lafage-Pochitaloff M, Soler G, Schluth C, Radford
I, Ottolenghi C, Bernard OA, et al: NUP98-HMGB3: A novel oncogenic
fusion. Leukemia. 24:654–658. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo S, Wang Y, Gao Y, Zhang Y, Chen M, Xu
M, Hu L, Jing Y, Jing F, Li C, et al: Knockdown of high mobility
group-box 3 (HMGB3) expression inhibits proliferation, reduces
migration, and affects chemosensitivity in gastric cancer cells.
Med Sci Monit. 22:3951–3960. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li M, Cai Y, Zhao H, Xu Z, Sun Q, Luo M,
Gu L, Meng M, Han X and Sun H: Overexpression of HMGB3 protein
promotes cell proliferation, migration and is associated with poor
prognosis in urinary bladder cancer patients. Tumour Biol.
36:4785–4792. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamada Y, Nishikawa R, Kato M, Okato A,
Arai T, Kojima S, Yamazaki K, Naya Y, Ichikawa T and Seki N:
Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell
aggressiveness and is involved in prostate cancer pathogenesis. J
Hum Genet. 63:195–205. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Han Y, Zhao Q, Zhou J and Shi R: miR-429
mediates tumor growth and metastasis in colorectal cancer. Am J
Cancer Res. 7:218–233. 2017.PubMed/NCBI
|
|
18
|
Sun Y, Shen S, Liu X, Tang H, Wang Z, Yu
Z, Li X and Wu M: MiR-429 inhibits cells growth and invasion and
regulates EMT-related marker genes by targeting Onecut2 in
colorectal carcinoma. Mol Cell Biochem. 390:19–30. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li L, Huang J, Ju Z, Li Q, Wang C, Qi C,
Zhang Y, Hou Q, Hang S and Zhong J: Multiple promoters and targeted
microRNAs direct the expressions of HMGB3 gene transcripts in dairy
cattle. Anim Genet. 44:241–250. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Song N, Liu B, Wu JL, Zhang RF, Duan L, He
WS and Zhang CM: Prognostic value of HMGB3 expression in patients
with non-small cell lung cancer. Tumour Biol. 34:2599–2603. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Elgamal OA, Park JK, Gusev Y,
Azevedo-Pouly AC, Jiang J, Roopra A and Schmittgen TD: Tumor
suppressive function of mir-205 in breast cancer is linked to HMGB3
regulation. PLoS One. 8:e764022013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gao J, Zou Z, Gao J, Zhang H, Lin Z, Zhang
Y, Luo X, Liu C, Xie J and Cai C: Increased expression of HMGB3: A
novel independent prognostic marker of worse outcome in patients
with esophageal squamous cell carcinoma. Int J Clin Exp Pathol.
8:345–352. 2015.PubMed/NCBI
|
|
23
|
Gong Y, Cao Y, Song L, Zhou J, Wang C and
Wu B: HMGB3 characterization in gastric cancer. Genet Mol Res.
12:6032–6039. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Z, Chang Y, Zhang J, Lu Y, Zheng L,
Hu Y, Zhang F and Li X, Zhang W and Li X: HMGB3 promotes growth and
migration in colorectal cancer by regulating WNT/β-catenin pathway.
PLoS One. 12:e01797412017. View Article : Google Scholar : PubMed/NCBI
|
